Xiao B, et al. - Via this meta-analysis of 85 randomized controlled trials, researchers assessed the relative risk (RR) of bleeding events associated with the use of antiangiogenic monoclonal antibodies, bevacizumab and ramucirumab. Using random-effects or fixed-effects models, RR and 95% CIs were calculated for all-grade and high-grade bleeding events associated with the angiogenesis inhibitors. Findings demonstrated a significantly increased risk of all-grade and high-grade bleeding related to antiangiogenic monoclonal antibodies. In lung cancer patients treated with bevacizumab, a significantly increased risk of all-grade and high-grade pulmonary hemorrhage was observed, however, no significant differences in the risk of all-grade and high-grade pulmonary hemorrhage was observed for ramucirumab.